Calcium channel blockers are not associated with increased risk of breast cancer, study finds

BMJ ◽  
2016 ◽  
pp. i3698
Author(s):  
Zosia Kmietowicz
Keyword(s):  
Breast Cancer ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Channel Blockers ◽  
Cancer Study ◽  
Breast Cancer Study ◽  
Increased Risk

Abstract 12688: Long Term Use of Calcium Channel Blockers and Risk of Breast Cancer Development

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Uyen T Lam ◽  
Stacey Knight ◽  
Tami L Bair ◽  
Viet T Le ◽  
Joseph B Muhlestein ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Positive Family History ◽  
Channel Blockers ◽  
Increased Risk ◽  
History Of ◽  
Incident Breast Cancer

Introduction: Calcium channel blockers (CCBs) are a mainstay in treating hypertension (HTN). Recently, Li et-al published a population based case-control study (JAMA 2013; 289:2354) reporting CCB use to be associated with incident breast cancer (odds ratio 2.6). We prospectively analyzed 2 Intermountain Healthcare (IHC) databases (db) to confirm or refute this provocative report. Methods: Two separate analyses were conducted using general patients (GP) seen at IHC and patients undergoing coronary angiography (CV) at IHC facilities. Subjects were females aged 50-70 with no history of breast cancer. Those prescribed CCB were matched 1:1 to subjects not on CCB based on age, race, tobacco, alcohol, body mass index, HTN and follow up time. Multivariable Cox proportional hazards regression was used for the primary analysis of time to incident breast cancer by CCB use adjusting for history of other cancers and family history of breast cancer. Results: A total of 2612 GP subjects (cases/controls) and 1106 CV subjects (cases/controls) were studied. In the GP db, there was a statistically significant increased risk of breast cancer for subjects using CCB (HR=1.58; 95% CI: 1.10-2.26). Risk was also associated with a positive family history (HR=2.79; 1.96-3.97) and a personal history of cancer (HR=1.87; 1.07-3.26). Breast cancer predominantly developed in <5 y of follow up (64% of cases). However, a reverse relationship was found in the CV db, where the HR was 0.51 (95% CI: 0.27-0.97). This observation was found despite consistent associations with several secondary outcomes, including for incident diabetes, coronary and renal disease. Conclusion: A modest association between CCB use and incident breast cancer was observed in the GP db, but results were not reproducible in the CV db. Given lack of a credible mechanism and failure of previous randomized CCB studies to detect a signal, we interpret these modest and conflicting associations to likely represent uncorrected confounding, e.g. prescriber bias or drug interactions. Similarly, we believe the results of Li et-al may represent confounding. Given the important role of CCBs in clinical medicine, further studies are warranted, including randomized trials to assess CCB safety with respect to breast cancer risk.

scholarly journals Calcium channel blockers and breast cancer incidence: An updated systematic review and meta-analysis of the evidence

2017 ◽  
Vol 50 ◽  
pp. 113-124 ◽  
Author(s):  
Cameron M. Wright ◽  
Rachael E. Moorin ◽  
Enayet K. Chowdhury ◽  
Bruno H. Stricker ◽  
Christopher M. Reid ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Calcium Channel ◽  
Cancer Incidence ◽  
Calcium Channel Blockers ◽  
Meta Analysis ◽  
Breast Cancer Incidence ◽  
Channel Blockers

scholarly journals Calcium Channel Blockers and Risk of Breast Cancer: A Meta-Analysis of 17 Observational Studies

PLoS ONE ◽  
2014 ◽  
Vol 9 (9) ◽  
pp. e105801 ◽  
Author(s):  
Wen Li ◽  
Qi Shi ◽  
Weibing Wang ◽  
Jianrong Liu ◽  
Qi Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Observational Studies ◽  
Meta Analysis ◽  
Channel Blockers

The long-term use of calcium channel blockers and the risk of breast cancer.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 1588-1588 ◽  
Author(s):  
Sara V. Soldera ◽  
Nathaniel Bouganim ◽  
Jamil Asselah ◽  
Hui Yin ◽  
Ralph Maroun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Channel Blockers

Use of Calcium Channel Blockers and Risk of Breast Cancer

Epidemiology ◽  
2016 ◽  
Vol 27 (4) ◽  
pp. 594-601 ◽  
Author(s):  
Laurent Azoulay ◽  
Sara Soldera ◽  
Hui Yin ◽  
Nathaniel Bouganim
Keyword(s):  
Breast Cancer ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Channel Blockers

scholarly journals A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome

eLife ◽  
2015 ◽  
Vol 4 ◽  
Author(s):  
Jefferson J Doyle ◽  
Alexander J Doyle ◽  
Nicole K Wilson ◽  
Jennifer P Habashi ◽  
Djahida Bedja ◽  
...  
Keyword(s):  
Aortic Aneurysm ◽  
Calcium Channel ◽  
Marfan Syndrome ◽  
Calcium Channel Blockers ◽  
Aortic Surgery ◽  
Antihypertensive Agents ◽  
Channel Blockers ◽  
Environment Interaction ◽  
Increased Risk ◽  
Deleterious Gene

Calcium channel blockers (CCBs) are prescribed to patients with Marfan syndrome for prophylaxis against aortic aneurysm progression, despite limited evidence for their efficacy and safety in the disorder. Unexpectedly, Marfan mice treated with CCBs show accelerated aneurysm expansion, rupture, and premature lethality. This effect is both extracellular signal-regulated kinase (ERK1/2) dependent and angiotensin-II type 1 receptor (AT1R) dependent. We have identified protein kinase C beta (PKCβ) as a critical mediator of this pathway and demonstrate that the PKCβ inhibitor enzastaurin, and the clinically available anti-hypertensive agent hydralazine, both normalize aortic growth in Marfan mice, in association with reduced PKCβ and ERK1/2 activation. Furthermore, patients with Marfan syndrome and other forms of inherited thoracic aortic aneurysm taking CCBs display increased risk of aortic dissection and need for aortic surgery, compared to patients on other antihypertensive agents.

Sign in / Sign up

Export Citation Format

Share Document